General
Preferred name
BI 653048
Synonyms
BI-653048 ()
P&D ID
PD064803
CAS
1198784-72-3
Tags
available
free of charge
probe
drug candidate
Drug Status
investigational
Max Phase
1.0
Probe info
Probe type
experimental probe
Probe sources
Chemical Probes.org
High-quality chemical probes
Open Science Probes
opnMe Portal
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION BI 653048 is a “dissociated” GR agonist (displaying different transcriptional regulatory profiles between gene transrepression and transactivation) with selectivity against other nuclear receptors (MR, PR) and improved drug-like properties like reduced CYP-inhibition across isoforms and reduced affinity for the hERG ion channel. For unkown reasons, the compound shows species selectivity with reduced mouse functional transrepression potency and is not suitable for evaluation in standard preclinical mouse models.
DESCRIPTION BI 653048 is a "dissociated" glucocorticoid receptor (GR) agonist (displaying different transcriptional regulatory profiles between gene transrepression and transactivation). This type of drug is designed to reduce the unwanted side-effects common to traditional GR agonists . It has favourable drug-like properties, but because it has reduced mouse functional transrepression potency it is not suitable for evaluation in standard preclinical mouse models. BI 653048 is synthesised as the phosphoric acid (H3PO4) cocrystal to optimise physicochemical properties, stability characteristics, solubility and bioavailability compared to the free form .
This ligand is one of the compounds available from Boehringer Ingelheim's opnMe molecular library. (GtoPdb)
DESCRIPTION BI 653048 is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC50 value of 55 nM[1]. BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms¡¯ activity and reduces affinity for the hERG ion channel (IC50>30 ¦ÌM)[2]. BI 653048 is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus[3].
MOA Agonist (Chemical Probes.org)
DESCRIPTION BI 653048 is a “dissociated” GR agonist (displaying different transcriptional regulatory profiles between gene transrepression and transactivation) with selectivity against other nuclear receptors (MR, PR) and improved drug-like properties like reduced CYP-inhibition across isoforms and reduced affinity for the hERG ion channel. For unknown reasons, the compound shows species selectivity with reduced mouse functional transrepression potency and is not suitable for evaluation in standard preclinical in vivo mouse models. (opnMe Portal)
Compound Sets
9
ChEMBL Drugs
CHEMBL3358954
Chemical Probes.org
bi-653048
CZ-OPENSCREEN Bioactive Library
EUbOPEN Chemogenomics Library
EUB0000314
Guide to Pharmacology
9715
High-quality chemical probes
PD064803
MedChem Express Bioactive Compound Library
HY-12946
Open Science Probes
BI 653048
opnMe Portal
gm-bi653048
External IDs
17
Properties
(calculated by RDKit )
Molecular Weight
515.15
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
3
cLogP
3.8
TPSA
126.14
Fraction CSP3
0.39
Chiral centers
1.0
Largest ring
6.0
QED
0.39
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Cytochrome P450
Glucocorticoid Receptor
HCV Protease
NR3C1
GR
Pathway
Anti-infection
Immunology/Inflammation
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Control name
BI-3047
Target class
NHR
Target subclass
Subfamily 3
Control
BI 3047
Recommended Cell Concentration
1 uM
Source data